Wedbush analyst Robert Driscoll downgraded Surface Oncology (SURF) to Neutral from Outperform after it was announced that Coherus Biosciences (CHRS) will acquire Surface in a stock-for-stock transaction.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SURF:
- Surface Oncology downgraded to Neutral from Buy at H.C. Wainwright
- Surface Oncology implements 50% workforce reduction
- Coherus to Acquire Surface Oncology
- Coherus Biosciences, Surface Oncology enter definitive merger agreement
- Surface Oncology (SURF) Q1 Earnings Cheat Sheet
Questions or Comments about the article? Write to editor@tipranks.com